Advertisement

Topics

Spark/Novartis eye gene therapy nears EU market – but at what price?

09:28 EDT 21 Sep 2018 | pharmaphorum

Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European regulators, paving the way for an EU licence in the coming months. A marketing authorisation from the European Commission is usuall...

Original Article: Spark/Novartis eye gene therapy nears EU market – but at what price?

NEXT ARTICLE

More From BioPortfolio on "Spark/Novartis eye gene therapy nears EU market – but at what price?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...